This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 9, 2013 /PRNewswire/ -- As Lipitor lawsuits (
http://www.thelipitorlawsuit.com/ ) alleging use of the statin caused patients to develop Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the Journal of the American Medical Association (JAMA) has published a new editorial that expresses concerns about the possible "statinazation" of the U.S. Its
December 2nd publication follows the issuance of new guidelines last month by the American Heart Association and the American College of Cardiology that could increase the use of Lipitor and other statins by millions of patients.
John P. A. Ioannidis, director of the Stanford Prevention Research Center at
Stanford University School of Medicine and author of the JAMA editorial, writes that the new guidelines could result in 40 million more Americans between the ages of 40 and 79 who do not have cardiovascular disease being prescribed statins. Among other things, Dr. Ioannidis points to the drugs' possible side effects, including diabetes and myopathy, and warns that the statinazation of America could "be one of the greatest achievements or one of the worst disasters of medical history."
"In light of the growing number of Lipitor diabetes lawsuits that have been filed in courts around the country, the concerns raised by Dr. Ioannidis merit further investigation. Patients considering statins, especially those who do not suffer from heart disease, should be fully apprised of their possible risks," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to alleged victims of Lipitor and diabetes.
Lipitor Diabetes Lawsuits
February 2012, the
U.S. Food & Drug Administration (FDA) ordered Pfizer, Inc. to add new warnings to the Lipitor label regarding an increased risk of new-onset diabetes in patients who took the cholesterol-lowering statin. The FDA acted after research reported in JAMA: Internal Medicine the preceding month revealed that post-menopausal women treated with Lipitor may be at an increased risk for developing the disease.
A study published just this past May in the British Medical Journal added to growing Lipitor diabetes concerns, after it reported that patients taking Lipitor had a 22 percent higher risk of new-onset diabetes.